Exciting SHIELD II Phase 3 Results Showcase Surgical Advancements

Author: Owen Jenkins Updated: 09-30-2025 09:02 AM

PolyPid Announces Significant SHIELD II Trial Outcomes

PolyPid Ltd. (NASDAQ: PYPD), a pioneering biopharma company focused on enhancing surgical outcomes, has recently unveiled that Dr. Shmuel Sharoni will showcase the topline results from its Phase 3 SHIELD II trial at the upcoming American College of Surgeons (ACS) Clinical Congress. This presentation is a notable opportunity for PolyPid to highlight their innovative strategies aimed at reducing surgical complications in abdominal colorectal surgeries.

Presentation Highlights

During the conference scheduled to take place in Chicago, Dr. Sharoni's talk will be focused on the efficacy of D-PLEX???, PolyPid's treatment designed to prevent surgical site infections. The presentation will take place on Sunday, October 5, 2025, at 11:30 AM CT during a session dedicated to high-impact clinical trials.

Conference Details

The ACS Clinical Congress will occur from October 4-7, 2025, at McCormick Place in Chicago. Attendees will gain insights into the latest research and advancements in surgical care through various presentations, including those from leading figures in the field such as Dr. Sharoni.

Understanding the SHIELD II Trial

The SHIELD II trial is a groundbreaking, multinational, randomized, and double-blind study designed to assess the efficiency of D-PLEX??? alongside standard surgical care. The trial successfully met its primary and all key secondary efficacy endpoints, demonstrating a remarkable 38% reduction in combined incidents of surgical site infections, reinterventions, or mortality.

Trial Outcomes

Moreover, the data indicates a notable 58% decline in surgical site infections among patients receiving the D-PLEX??? treatment. These findings are monumental as they pave the way for safer surgical practices and improved recovery outcomes for patients undergoing colorectal surgeries.

About PolyPid and D-PLEX???

PolyPid Ltd. is committed to transforming surgical protocols with its innovative PLEX technology that allows for locally administered therapeutics with controlled and prolonged release. D-PLEX???, the company's flagship product, aims to deliver localized medication effectively, thus optimizing treatment durations and improving clinical outcomes in surgical settings.

Future Prospects

Looking ahead, PolyPid plans to submit a New Drug Application (NDA) for D-PLEX??? in early 2026, marking a significant milestone in their journey to elevate surgical care standards. The company's pipeline extends beyond surgical applications, delving into therapeutic solutions for areas such as oncology, obesity, and diabetes.

Contact Information

The management team at PolyPid will be present at the ACS Clinical Congress and welcomes inquiries regarding their groundbreaking work. For scheduling meetings or further inquiries, interested parties can email IR@Polypid.com.

Frequently Asked Questions

What is PolyPid's focus in the biopharma industry?

PolyPid Ltd. specializes in developing surgical therapeutics that enhance patient outcomes through innovative drug delivery systems.

What are the results of the SHIELD II trial?

The SHIELD II trial demonstrated a 38% reduction in surgical site infections and a 58% decrease in overall complications when using D-PLEX??? alongside standard care.

When will PolyPid submit their NDA for D-PLEX????

PolyPid plans to submit their New Drug Application for D-PLEX??? in early 2026.

Who is presenting the results of the SHIELD II trial?

Dr. Shmuel Sharoni will be presenting the trial results at the ACS Clinical Congress in October 2025.

Where can I learn more about PolyPid?

For more information, you can visit http://www.polypid.com.

About The Author

Hi there I'm 38-year-old author and financial consultant Owen Jenkins. Having worked in the financial sector for more than ten years, I am well-versed in the subtleties and complexity that mold our financial environment. Following a degree in finance, I worked in a number of financial institutions honing my abilities in market analysis, financial planning, and investment strategies.

My love is teaching others about investing and personal finance. My goal in writing many books and articles has been to demystify financial ideas and give readers the information they need to make wise financial decisions. I write with a direct, useful style that emphasizes doable suggestions for daily living.

Along with writing, I lead webinars and seminars where I impart knowledge on how to successfully negotiate the financial world. I also write for financial journals and show up as a guest expert on financial news programs a lot. Whether they are new to investing or want to improve their approach, my mission is to enable people to take charge of their financial futures.

Beyond work, I like to hike, play the guitar, and spend time with my family. I think that balance is crucial and want to encourage people to strike a balance between their financial aspirations and their hobbies. I want to help people succeed and achieve financial security through my work, so having a good influence.

Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.